Immunodeficiency 30, or IMD30 for short, results from an autosomal recessive inherited IL12RB1 deficiency.
Images (1)
Immunodeficiency 30D81.8
DefinitionThis section has been translated automatically.
EtiopathogenesisThis section has been translated automatically.
Activated T lymphocytes and natural killer lymphocytes from IMD30 patients do not express IL12RB1 on their surface or (more rarely) non-functional IL12RB1 on their surface. IMD30 patients therefore do not respond to IL12 and IL23, and the clinical picture of patients with IL12RB1 deficiency is similar to that of patients with IL12B deficiency. The consequence of IL12RB1 deficiency is mycobacteriosis and salmonellosis. Salmonellosis occurs in about half of patients with IL12RB1 deficiency. Somewhat less common are tuberculosis infections or other infections.
Progression/forecastThis section has been translated automatically.
IMD30 has low penetrance; patients have a relatively mild disease course and a good prognosis (Al-Muhsen et al. 2008).
Case report(s)This section has been translated automatically.
Fieschi et al (2003) identified 41 patients in 29 families from 17 countries in Africa, the Americas, Europe, and Asia with complete IL12RB1 surface expression deficiency. Opportunistic infections in childhood with low-virulence Salmonella and mycobacteria were observed in 34 patients. 3 patients had clinical tuberculosis, and 1 patient suffered from salmonellosis. Salmonellosis, but not mycobacterial infections, recurred. Death before 8 years of age occurred in 5 patients, 3 due to M. avium in non-BCG-vaccinated children and 2 due to disseminated BCG. Fieschi et al (2003) concluded that the overall prognosis was good because of the broad resistance to infection, low clinical penetrance, and favorable outcome of the infections.
LiteratureThis section has been translated automatically.
- Al-Muhsen S et al (2008) The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immun 122: 1043-1051.
- Altare F et al (1998) Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280: 1432-1435.
- de Jong R et al. (1998) Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280: 1435-1438.
- Fieschi C et al (2003) Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta-1 deficiency: medical and immunological implications. J Exp Med 197: 527-535.
- Ozbek N et al (2005) Interleukin-12 receptor beta-1 chain deficiency in a child with disseminated tuberculosis. Clin. Infect. Dis 40: e55-e58.